REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib

Andrew X. Zhu; Yoon-Koo Kang; Chia-Jui Yen; Richard S. Finn; Peter R. Galle; Josep M. Llovet; Eric Assenat; Giovanni Brandi; Ho Yeong Lim; Marc Pracht; Kun-Ming Rau; Philippe Merle; Kenta Motomura; Izumi Ohno; Bruno Daniele; Dongbok Shin; Guido Gerken; Paolo Abada; Yanzhi Hsu; Masatoshi Kudo

doi:10.1200/JCO.2018.36.15_suppl.4003

Retour

REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib

Article de revue

Avec comité de lecture

REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib

Andrew X. Zhu, Yoon-Koo Kang, Chia-Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Eric Assenat, Giovanni Brandi, Ho Yeong Lim, Marc Pracht, …

Journal of clinical oncology, Vol.36(15_suppl), pp.4003-4003

20/05/2018

DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.4003

Résumé

Abstract only

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib
Créateurs - sans rôle: Andrew X. Zhu - Harvard Medical School
Yoon-Koo Kang - Asan Medical Center
Chia-Jui Yen - National Cheng Kung University Hospital, Tainan, Taiwan
Richard S. Finn - University of California, Los Angeles
Peter R. Galle - Universitätsmedizin, Mainz, Germany
Josep M. Llovet - Icahn School of Medicine at Mount Sinai
Eric Assenat - CHU de Montpellier, Montpellier, France
Giovanni Brandi - Policlinico Sant' Orsola-Malpighi, Bologna, Italy
Ho Yeong Lim - Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
Marc Pracht - Centre Eugène Marquis
Kun-Ming Rau - Chang Gung Memorial Hospital Kaohsiung Branch, Kaohsiung, Taiwan
Philippe Merle - Hôpital de la Croix-Rousse
Kenta Motomura - Aso Iizuka Hospital
Izumi Ohno - Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan
Bruno Daniele - G.Rummo Hospital, Benevento, Italy
Dongbok Shin - Gachon University Gil Medical Center, Incheon, Korea South
Guido Gerken - Universtitätsklinikum Essen AöR, Essen, Germany
Paolo Abada - Eli Lilly and Company, Indianapolis, IN
Yanzhi Hsu - Eli Lilly and Company, New York, NY
Masatoshi Kudo - Kindai University
Détails de publication: Journal of clinical oncology, Vol.36(15_suppl), pp.4003-4003
Identifiants: 99139678609311
Unité académique: Institut de Génétique Moléculaire de Montpellier - IGMM
Langue: English
Type de ressource: Journal article